Stockreport

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Ph [Read more]